Novartis Type 2 Diabetes Drug Approved for Use in Japan


Novartis anounced that three medicines have been approved for use in Japan, among them Equa® (vildagliptin), marketed as Galvus® in the European Union, for the treatment of type 2 diabetes.
Equa has been approved in Japan for the treatment of type 2 diabetes, as monotherapy or in combination with a sulfonylurea. As a DPP-4 inhibitor, Equa works by targeting the dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes.
An estimated 7 million people in Japan have type 2 diabetes.

Leave a Reply

1 Comment threads
0 Thread replies
Most reacted comment
Hottest comment thread
1 Comment authors
The poor diabetic Recent comment authors
newest oldest most voted
Notify of
The poor diabetic
The poor diabetic

are these drugs available in the US market?

Copyright © 2009-2018 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.